
A Medicxi-backed startup looks to tackle treatment-resistant blood cancers, and it's going after AML first
In the hardest-to-treat blood cancers, resistance to therapy is an existential problem for drug developers looking to permanently stave off tumors. A small biotech is chasing an emerging pathway to stop tumors’ ability to resist treatment, and its work has caught the eye of a couple of big-name investors.
Kurome Therapeutics snared a $15 million Series A round it will use to identify and develop a lead program from its platform looking at dual inhibitors of the IRAK1/4 signaling pathway and FLT3 protein receptors on heme blasts to crack treatment-resistant tumors, the biotech said Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.